Summary
Global Markets Direct’s, ‘OPKO Health, Inc. - Product Pipeline Review - 2016’, provides an overview of the OPKO Health, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by OPKO Health, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of OPKO Health, Inc.
- The report provides overview of OPKO Health, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses OPKO Health, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features OPKO Health, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate OPKO Health, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for OPKO Health, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding OPKO Health, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
OPKO Health, Inc. Snapshot 7
OPKO Health, Inc. Overview 7
Key Information 7
Key Facts 7
OPKO Health, Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
OPKO Health, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
OPKO Health, Inc. - Pipeline Products Glance 16
OPKO Health, Inc. - Late Stage Pipeline Products 16
Filing rejected/Withdrawn Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
OPKO Health, Inc. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
OPKO Health, Inc. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
OPKO Health, Inc. - Unknown Stage Pipeline Products 22
Unknown Products/Combination Treatment Modalities 22
OPKO Health, Inc. - Drug Profiles 23
calcifediol MR 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
fermagate 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
MOD-4023 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
CTAP-201 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
lunacalcipol 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MOD-5014 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MOD-6031 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CTA-091 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CUR-1916 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Oncology 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
MOD-1001 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
MOD-1002 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
MOD-6030 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MOD-7023 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MOD-9013 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
MOD-9017 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Oligonucleotide for Mucopolysaccharidosis I 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Oligonucleotide For Rett Syndrome 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecule for Hearing Loss 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecule for Oncology 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
SR-3306 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Recombinant Protein for Atherosclerosis 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Recombinant Protein for Rheumatoid Arthritis 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecules to Inhibit Lipoprotein Signal Peptidase for Bacterial Infections 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
OPK-0018 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
OPKO Health, Inc. - Pipeline Analysis 55
OPKO Health, Inc. - Pipeline Products by Target 55
OPKO Health, Inc. - Pipeline Products by Route of Administration 57
OPKO Health, Inc. - Pipeline Products by Molecule Type 58
OPKO Health, Inc. - Pipeline Products by Mechanism of Action 59
OPKO Health, Inc. - Recent Pipeline Updates 61
OPKO Health, Inc. - Dormant Projects 76
OPKO Health, Inc. - Company Statement 77
OPKO Health, Inc. - Locations And Subsidiaries 78
Head Office 78
Other Locations & Subsidiaries 78
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81
List of Tables
OPKO Health, Inc., Key Information 7
OPKO Health, Inc., Key Facts 7
OPKO Health, Inc. - Pipeline by Indication, 2016 9
OPKO Health, Inc. - Pipeline by Stage of Development, 2016 11
OPKO Health, Inc. - Monotherapy Products in Pipeline, 2016 12
OPKO Health, Inc. - Combination Treatment Modalities in Pipeline, 2016 13
OPKO Health, Inc. - Out-Licensed Products in Pipeline, 2016 14
OPKO Health, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 15
OPKO Health, Inc. - Filing rejected/Withdrawn, 2016 16
OPKO Health, Inc. - Phase III, 2016 17
OPKO Health, Inc. - Phase II, 2016 18
OPKO Health, Inc. - Phase I, 2016 19
OPKO Health, Inc. - Preclinical, 2016 20
OPKO Health, Inc. - Discovery, 2016 21
OPKO Health, Inc. - Unknown, 2016 22
OPKO Health, Inc. - Pipeline by Target, 2016 55
OPKO Health, Inc. - Pipeline by Route of Administration, 2016 57
OPKO Health, Inc. - Pipeline by Molecule Type, 2016 58
OPKO Health, Inc. - Pipeline Products by Mechanism of Action, 2016 60
OPKO Health, Inc. - Recent Pipeline Updates, 2016 61
OPKO Health, Inc. - Dormant Developmental Projects,2016 76
OPKO Health, Inc., Subsidiaries 78
List of Figures
OPKO Health, Inc. - Pipeline by Top 10 Indication, 2016 9
OPKO Health, Inc. - Pipeline by Stage of Development, 2016 11
OPKO Health, Inc. - Monotherapy Products in Pipeline, 2016 12
OPKO Health, Inc. - Out-Licensed Products in Pipeline, 2016 14
OPKO Health, Inc. - Pipeline by Top 10 Target, 2016 55
OPKO Health, Inc. - Pipeline by Route of Administration, 2016 57
OPKO Health, Inc. - Pipeline by Molecule Type, 2016 58
OPKO Health, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 59
